Modulating the delicate glial-neuronal interactions in neuropathic pain: Promises and potential caveats

Neuroscience and Biobehavioral Reviews

Volumn 45, Issue , 2014, Pages 19-27

  Tiwari, Vinod ^a   Guan, Yun ^a   Raja, Srinivasa N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocytes; Glia; Microglia; Pain

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMPA RECEPTOR; AZD 2423; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID 2 RECEPTOR AGONIST; CHEMOKINE RECEPTOR CCR2; GELATINASE B; GLUTAMIC ACID; IBUDILAST; INTERLEUKIN 10; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; NESS 400; PROPENTOFYLLINE; PROSTAGLANDIN E2; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; EVODENOSON; MORPHINE; NALOXONE;

ASTROCYTE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; MICROGLIA; NERVE CELL; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SPINAL GANGLION; ANTIINFLAMMATORY ACTIVITY; CELL PROTECTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLIAL NEURONAL INTERACTION; NEUROMODULATION; NEUROTOXICITY; PHENOTYPE; ANIMAL; DRUG EFFECTS; GLIA; NEURALGIA; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; NEURALGIA; NEUROGLIA; NEURONS;

EID: 84901409983     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.05.002     Document Type: Review

References (101)

1. Anand U., Otto W.R., Sanchez-Herrera D., Facer P., Yiangou Y., Korchev Y., Birch R., Benham C., Bountra C., Chessell I.P., Anand P. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008, 138(3):667-680.
2. Ashton J.C., Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 2007, 5(2):73-80.
3. Barkhof F., Hulst H.E., Drulovic J., Uitdehaag B.M., Matsuda K., Landin R., MN166-001 Investigators Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?. Neurology 2010, 74(March (13)):1033-1040.
4. Battista D., Ferrari C.C., Gage F.H., Pitossi F.J. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur. J. Neurosci. 2006, 23:83-93.
5. Beltramo M., Bernardini N., Bertorelli R., Campanella M., Nicolussi E., Fredduzzi S., Reggiani A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 2006, 23(March (6)):1530-1538.
6. Besson J.M. The neurobiology of pain. Lancet 1999, 353:1610-1615.
7. Bhasin M., Wu M., Tsirka S.E. Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis. BMC Immunol. 2007, 8:10.
8. Butovsky O. Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7-2 (CD86) and prevention of cyst formation. FASEB J. 2001, 15:1065-1067.
9. Cheng Y., Albrecht B.K., Brown J., Buchanan J.L., Buckner W.H., DiMauro E.F., Emkey R., et al. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists. J. Med. Chem. 2008, 51(16):5019-5034.
10. Chiang C.Y., Wang J., Xie Y.F., et al. Astroglial glutamate-glutamine shuttle is involved in central sensitization of nociceptive neurons in rat medullary dorsal horn. J. Neurosci. 2007, 27:9068-9076.
11. Clark A.K., Yip P.K., Grist J., Gentry C., Staniland A.A., Marchand F., Dehvari M., Wotherspoon G., Winter J., Ullah J., Bevan S., Malcangio M. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(June (25)):10655-10660.
12. Clarke C.B., Suter M.R., Gosselin R.D. Glial cells and chronic pain: from the laboratory to clinical hope. Rev. Med. Suisse 2013, 9(June (392)):1342-1345.
13. Cohen S.P., Galvagno S.M., Plunkett A., Harris D., Kurihara C., Turabi A., Rehrig S., Buckenmaier C.C., Chelly J.E. A multicenter, randomized, controlled study evaluating preventive etanercept on postoperative pain after inguinal hernia repair. Anesth. Analg. 2013, 116(February (2)):455-462.
14. Cohen S.P., White R.L., Kurihara C., Larkin T.M., Chang A., Griffith S.R., Gilligan C., Larkin R., Morlando B., Pasquina P.F., Yaksh T.L., Nguyen C. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann. Intern. Med. 2012, 156(April (8)):551-559.
15. Colburn R.W., DeLeo J.A., Rickman A.J., Yeager M.P., Kwon P., Hickey W.F. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J. Neuroimmunol. 1997, 79(November (2)):163-175.
16. Colburn R.W., Rickman A.J., DeLeo J.A. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp. Neurol. 1999, 157(June (2)):289-304.
17. Coull J.A., Beggs S., Boudreau D., Boivin D., Tsuda M., Inoue K., Gravel C., Salter M.W., De Koninck Y. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005, 438(December (7070)):1017-1021.
18. Del Valle L., Schwartzman R.J., Alexander G. Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. Brain Behav. Immun. 2009, 23(January (1)):85-91.
19. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132(3):237-251.
20. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J., Shytle R.D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2005, 2(December):29.
21. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
22. Ellis A., Wieseler J., Favret J., Johnson K.W., Rice K.C., Maier S.F., Falci S., Watkins L.R. Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. J. Pain 2014, 15(4):407-421.
23. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49(January (1)):67-79.
24. Finnerup N.B., Sindrup S.H., Jensen T.S. The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150(September (3)):573-581.
25. Fox R.J. Primary neuroprotection: the Holy Grail of multiple sclerosis therapy. Neurology 2010, 74(March (13)):1018-1019.
26. Frampton M., Harvey R.J., Kirchner V. Propentofylline for dementia. Cochrane Database Syst. Rev. 2003, (2):CD002853.
27. Glezer I., Simard A.R., Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience 2007, 147(July (4)):867-883.
28. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
29. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
30. Gourine A.V., Kasymov V., Marina N., Tang F., Figueiredo M.F., Lane S., Teschemacher A.G., Spyer K.M., Deisseroth K., Kasparov S. Astrocytes control breathing through pH-dependent release of ATP. Science 2010, 329(July (5991)):571-575.
31. Hald A., Nedergaard S., Hansen R.R., Ding M., Heegaard A.M. Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur. J. Pain 2009, 13:138-145.
32. Hamann S., Sloan P.A., Witt W. Low-dose intrathecal naloxone to enhance intrathecal morphine analgesia: a case report. J. Opioid Manage. 2008, 4(4):251-254.
33. Han X., Chen M., Wang F., Windrem M., Wang S., Shanz S., Xu Q., Oberheim N.A., Bekar L., Betstadt S., Silva A.J., Takano T., Goldman S.A., Nedergaard M. Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. Cell Stem Cell 2013, 12(March (3)):342-353.
34. Hutchinson M.R., Zhang Y., Brown K., Coats B.D., Shridhar M., Sholar P.W., Patel S.J., Crysdale N.Y., Harrison J.A., Maier S.F., Rice K.C., Watkins L.R. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci. 2008, 28(July (1)):20-29.
35. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(8):3093-3098.
36. 11C]PK11195 PET imaging of spinal glial activation after nerve injury in rats. Neuroimage 2013, October (79):121-128.
37. Inoue K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol. Therapeut. 2006, 109:210-226.
38. Jessen K.R., Mirsky R. Glial cells in the enteric nervous system contain glial fibrillary acidic protein. Nature 1980, 286(August (5774)):736-737.
39. Ji B., Maeda J., Sawada M., Ono M., Okauchi T., Inaji M., Zhang M.R., et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J. Neurosci. 2008, 28(47):12255-12267.
40. Ji R.R., Berta T., Nedergaard M. Glia and pain. Is chronic pain a gliopathy?. Pain 2013, pii:S0304-3959(13)00330-8.
41. Kallendrusch S., Kremzow S., Nowicki M., Grabiec U., Winkelmann R., Benz A., Kraft R., Bechmann I., Dehghani F., Koch M. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Glia 2013, [Epub ahead of print].
42. Kalliomäki J., Attal N., Jonzon B., Bach F.W., Huizar K., Ratcliffe S., Eriksson B., Janecki M., Danilov A., Bouhassira D., AZD2423 PTN Study Group A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain 2013, 154(May (5)):761-767.
43. Kawasaki Y., Xu Z.Z., Wang X., Park J.Y., Zhuang Z.Y., Tan P.H., Gao Y.J., Roy K., Corfas G., Lo E.H., Ji R.R. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat. Med. 2008, 14(March (3)):331-336.
44. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., Friedman H. The cannabinoid system and immune modulation. J. Leukoc. Biol. 2003, 74(4):486-496.
45. Lai A.Y., Todd K.G. Differential regulation of trophic and proinflammatory microglial effectors is dependent on severity of neuronal injury. Glia 2008, 56:259-270.
46. Ledeboer A., Hutchinson M.R., Watkins L.R., Johnson K.W. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs 2007, 16(July (7)):935-950.
47. Ledeboer A., Liu T., Shumilla J.A., Mahoney J.H., Vijay S., Gross M.I., Vargas J.A., Sultzbaugh L., Claypool M.D., Sanftner L.M., Watkins L.R., Johnson K.W. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006, 2(November (4)):279-291.
48. Lee B.S., Jun I.G., Kim S.H., Park J.Y. Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in a rat model of neuropathic pain. J. Korean Med. Sci. 2013, 28(February (2)):308-314.
49. Liu Y., Walter S., Stagi M., Cherny D., Letiembre M., Schulz-Schaeffer W., Heine H., Penke B., Neumann H., Fassbender K. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005, 128:1778-1789.
50. Loram L.C., Harrison J.A., Sloane E.M., Hutchinson M.R., Sholar P., Taylor F.R., Berkelhammer D., Coats B.D., Poole S., Milligan E.D., et al. Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J. Neurosci. 2009, 29(November (44)):14015-14025.
51. Loram L.C., Taylor F.R., Strand K.A., Harrison J.A., Rzasalynn R., Sholar P., Rieger J., Maier S.F., Watkins L.R. Intrathecal injection of adenosine 2A receptor agonists reversed neuropathic allodynia through protein kinase (PK)A/PKC signaling. Brain Behav. Immun. 2013, [Epub ahead of print].
52. Lu W., Bhasin M., Tsirka S.E. Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J. Neurosci. 2002, 22:10781-10789.
53. Luo X.G., Chen S.D. The changing phenotype of microglia from homeostasis to disease. Transl. Neurodegener. 2012, 1:9.
54. Luongo L., Guida F., Boccella S., Bellini G., Gatta L., Rossi F., de Novellis V., Maione S. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets 2013, 12(February (1)):45-54.
55. Luongo L., Guida F., Imperatore R., Napolitano F., Gatta L., Cristino L., Giordano C., Siniscalco D., Di Marzo V., Bellini G., Petrelli R., Cappellacci L., Usiello A., de Novellis V., Rossi F., Maione S. The A1 adenosine receptor as a new player in microglia physiology. Glia 2014, 62:122-132.
56. Luongo L., Palazzo E., Tambaro S., Giordano C., Gatta L., Scafuro M.A., Rossi F.S., Lazzari P., Pani L., de Novellis V., Malcangio M., Maione S. 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol. Dis. 2010, 37:177-185.
57. Malm T.M., Koistinaho M., Pärepalo M., Vatanen T., Ooka A., Karlsson S., Koistinaho J. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 2005, 18(February (1)):134-142.
58. Manzanares J., Julian M., Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr. Neuropharmacol. 2006, 4(July (3)):239-257.
59. Meme W., Calvo C.F., Froger N., Ezan P., Amigou E., Koulakoff A., Giaume C. Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid. FASEB J. 2006, 20:494-496.
60. Miller A.M., Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharmacol. 2008, 153(January (2)):299-308.
61. Milligan E.D., Penzkover K.R., Soderquist R.G., Mahoney M.J. Spinal interleukin-10 therapy to treat peripheral neuropathic pain. Neuromodulation 2012, 15(November-December (6)):520-526. (discussion 526).
62. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 2009, 10:23-36.
63. Molina-Holgado F., Pinteaux E., Moore J.D., Molina-Holgado E., Guaza C., Gibson R.M., Rothwell N.J. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 2003, 23(July (16)):6470-6474.
64. Nakajima K., Kohsaka S. Microglia: activation and their significance in the central nervous system. J. Biochem. 2001, 130(August (2)):169-175.
65. Núñez E., Benito C., Pazos M.R., Barbachano A., Fajardo O., González S., Tolón R.M., Romero J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 2004, 53(September (4)):208-213.
66. Oberheim N.A., Takano T., Han X., He W., Lin J.H., Wang F., Xu Q., Wyatt J.D., Pilcher W., Ojemann J.G., Ransom B.R., Goldman S.A., Nedergaard M. Uniquely hominid features of adult human astrocytes. J. Neurosci. 2009, 29(March (10)):3276-3287.
67. Ohta H., Ishizaka T., Tatsuzuki M., Yoshinaga M., Iida I., Yamaguchi T., Tomishima Y., Futaki N., Toda Y., Saito S. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorg. Med. Chem. 2008, 16(3):1111-1124.
68. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
69. Orr A.G., Orr A.L., Li X.J., Gross R.E., Traynelis S.F. Adenosine A(2A) receptor mediates microglial process retraction. Nat. Neurosci. 2009, 12:872-878.
70. Racz I., Nadal X., Alferink J., Baños J.E., Rehnelt J., Martín M., Pintado B., Gutierrez-Adan A., Sanguino E., Manzanares J., Zimmer A., Maldonado R. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J. Neurosci. 2008, 28:12125-12135.
71. Racz I., Nadal X., Alferink J., Banos J.E., Rehnelt J., Martin M., Pintado B., Gutierrez-Adan A., Sanguino E., Bellora N., Manzanares J., Zimmer A., Maldonado R. Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J. Neurosci. 2008, 28:12136-12145.
72. Ramirez G., Toro R., Dobeli H., von Bernhardi R. Protection of rat primary hippocampal cultures from A beta cytotoxicity by pro-inflammatory molecules is mediated by astrocytes. Neurobiol. Dis. 2005, 19:243-254.
73. Ren K., Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr. Opin. Anaesthesiol. 2008, 21(October (5)):570-579.
74. Rolan P., Hutchinson M., Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin. Pharmacother. 2009, 10(December (17)):2897-2904.
75. Rolan P. Methods for targeting glial activation in the treatment of patients with chronic pain. Mechanisms and Treatment of Neuropathic Pain, Annual Meeting: Snowbird 2007 November.
76. Romero-Sandoval A., Nutile-McMenemy N., DeLeo J.A. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008, 108(April (4)):722-734.
77. Sawada H., Suzuki H., Nagatsu T., Sawada M. Neuroprotective and neurotoxic phenotypes of activated microglia in neonatal mice with respective MPTP and ethanol-induced brain injury. Neurodegener. Dis. 2010, 7:64-67.
78. Scholz J., Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 2007, 10:1361-1368.
79. Sloan P., Hamann S. Ultra-low-dose opioid antagonists to enhance opioid analgesia. J. Opioid Manage. 2006, 2(September-October (5)):295-304.
80. Sloane E., Langer S., Jekich B., Mahoney J., Hughes T., Frank M., Seibert W., Huberty G., Coats B., Harrison J., Klinman D., Poole S., Maier S., Johnson K., Chavez R., Watkins L.R., Leinwand L., Milligan E. Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain. Gene Ther. 2009, 16(October (10)):1210-1222.
81. Soderquist R.G., Sloane E.M., Loram L.C., Harrison J.A., Dengler E.C., Johnson S.M., Amer L.D., Young C.S., Lewis M.T., Poole S., Frank M.G., Watkins L.R., Milligan E.D., Mahoney M.J. Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm. Res. 2010, 27(May (5)):841-854.
82. Sorge R.E., Trang T., Dorfman R., Smith S.B., Beggs S., Ritchie J., Austin J.S., Zaykin D.V., Vander Meulen H., Costigan M., Herbert T.A., Yarkoni-Abitbul M., Tichauer D., Livneh J., Gershon E., Zheng M., Tan K., John S.L., Slade G.D., Jordan J., Woolf C.J., Peltz G., Maixner W., Diatchenko L., Seltzer Z., Salter M.W., Mogil J.S. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat. Med. 2012, 18(March (4)):595-599.
83. Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440(April (7087)):1054-1059.
84. Stephenson D.T., Arneric S.P. Neuroimaging of pain: advances and future prospects. J. Pain 2008, 9(July (7)):567-579.
85. Suzumura A., Ito A., Yoshikawa M., Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999, 837(August (1-2)):203-212.
86. Svensson C.I., et al. Spinal p38b isoform mediates tissue injury-induced hyperalgesia and spinal sensitization. J. Neurochem. 2005, 92:1508-1520.
87. Sweitzer S., De Leo J. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain. Handb Exp Pharmacol. 2011, 200:235-250.
88. Toth C., Mawani S., Brady S., Chan C., Liu C., Mehina E., Garven A., Bestard J., Korngut L. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012, 153(Octoa):2073-2082.
89. Tran P.B., Miller R.J. Chemokine receptors: signposts to brain development and disease. Nat. Rev. Neurosci. 2003, 4(June (6)):444-455.
90. Vallejo R., Tilley D.M., Vogel L., Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract. 2010, 10(May-June (3)):167-184.
91. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310(5746):329-332.
92. Vincent V.A., Van Dam A.M., Persoons J.H., Schotanus K., Steinbusch H.W., Schoffelmeer A.N., Berkenbosch F. Gradual inhibition of inducible nitric oxide synthase but not of interleukin-1 beta production in rat microglial cells of endotoxin-treated mixed glial cell cultures. Glia 1996, 17:94-102.
93. von Bernhardi R., Eugenin J. Microglial reactivity to beta-amyloid is modulated by astrocytes and proinflammatory factors. Brain Res. 2004, 1025:186-193.
94. Watkins L.R., Hutchinson M.R., Milligan E.D., Maier S.F. Listening and talking to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res. Rev. 2007, 56:148-169.
95. Wieseler-Frank J., Maier S.F., Watkins L.R. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005, 14:166-174.
96. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353(June (9168)):1959-1964.
97. Wynn T.A., Thompson R.W., Cheever A.W., Mentink-Kane M.M. Immunopathogenesis of schistosomiasis. Immunol. Rev. 2004, 201:156-167.
98. Yao B.B., Hsieh G., Daza A.V., Fan Y., Grayson G.K., Garrison T.R., El Kouhen O., et al. Characterization of a cannabinoid CB2 receptor-selective agonist. A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J. Pharmacol. Exp. Ther. 2009, 328(1):141-151.
99. 11C]DAA 1106. Biol. Psychiatry 2008, 64(10):835-841.
100. Zhang J., De Koninck Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J. Neurochem. 2006, 97(May (3)):772-783.
101. Zhao P., Waxman S.G., Hains B.C. Modulation of thalamic nociceptive processing after spinal cord injury through remote activation of thalamic microglia by cysteine cysteine chemokine ligand 21. J. Neurosci. 2007, 27(August (33)):8893-8902.